PARIS — Beiersdorf AG said Wednesday that it will collaborate with Insilico Medicine, a biotech company using artificial intelligence for drug discovery and aging research, to find new, safe bioactive ingredients that can be used as the basis for creating skin-care products.
“As part of our open innovation culture, we are always looking for new technologies and partners with strengths that compliment ours,” said May Shana’a, senior corporate vice president, research and development, at Beiersdorf. “We are able to evaluate new active ingredients significantly more quickly and more efficiently by simulating biologic effects in silico. This enables us to cater even better to the consumers’ as-yet unmet skin-care needs.”
Source: Read Full Article